Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : Pfizer says it told India there no safety concern with its COVID-19 vaccine

05/03/2021 | 02:06pm EDT

NEW DELHI, May 3 (Reuters) - Pfizer Inc said on Monday it told the Indian government that there was no concern over the safety of its COVID-19 vaccine, as the country insists on small local trials for foreign shots despite a record surge in infections and shortage of doses.

The government in mid-April made it easier for foreign vaccines approved in the West and Japan to sell in India, though companies would still have to initiate a local clinical trial within 30 days of receiving emergency use authorization. Previously, companies were required to do the trial prior to approval.

India has invited Pfizer, Johnson & Johnson and Moderna Inc to sell their vaccines to the country but none have applied to do so yet.

Pfizer, however, said it is holding fresh talks with the government after having withdrawn its initial application in February over the earlier local trial rule.

"Pfizer’s application for emergency use authorization was supported with data that shows an overall efficacy rate of 95% with no safety concerns," a company spokeswoman told Reuters, when asked if it had sought an exception even to the current trial rule in its discussions with the government.

She added that the safety and efficacy data had been backed by regulatory authorities in the United States, Britain, Japan and the World Health Organization - agencies that India endorses.

Pfizer, which produces the vaccine with German partner BioNTech SE, reiterated that it would supply doses only through government contracts.

Asked about the vaccine's ultra-low temperature storage requirements - minus 70 degrees Celsius (-90 F) - Pfizer said the company could deliver the shot to vaccination centers using its specially designed, temperature-controlled thermal shippers.

It said doses could be stored in ultra-low-temperature freezers for up to six months, in the shippers for up to 30 days by refilling them with dry ice every five days, or in common refrigeration and freezer units for five days. (Reporting by Krishna N. Das; Editing by Bill Berkrot)


© Reuters 2021
All news about MODERNA, INC.
05:32pASTRAZENECA  : Experts call on Canada to use COVAX doses of AstraZeneca or give ..
AQ
02:40pWhy the CDC Told Fully Vaccinated Americans They Didn't Need to Wear Face Mas..
DJ
02:30pMODERNA  : COVID SCIENCE-Delayed 2nd Pfizer/BioNTech shot boosts antibodies in e..
RE
02:29pMODERNA  : U.S. administers 268.4 mln doses of COVID-19 vaccines - CDC
RE
02:22pMODERNA  : U.S. CDC Says Delivered 341.9 Million Doses Of Covid-19 Vaccine As Of..
RE
01:59pPFIZER  : Federal officials lay out road map for post-vaccine life as third wave..
AQ
01:18pMODERNA  : The latest news on COVID-19 developments in Canada
AQ
11:24aMODERNA  : Nova Scotia offers COVID-19 vaccine appointments to people aged 35 an..
AQ
04:47aWho have provinces pegged to receive COVID-19 vaccines in the coming weeks?
AQ
02:42aSamsung Biologics Rallies on Possible Moderna Covid-19 Vaccine Deal
DJ
More news
Financials (USD)
Sales 2021 18 363 M - -
Net income 2021 10 203 M - -
Net cash 2021 11 650 M - -
P/E ratio 2021 6,54x
Yield 2021 -
Capitalization 64 799 M 64 799 M -
EV / Sales 2021 2,89x
EV / Sales 2022 2,79x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 166,60 $
Last Close Price 161,38 $
Spread / Highest target 43,1%
Spread / Average Target 3,23%
Spread / Lowest Target -48,6%
EPS Revisions
Managers and Directors
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.43.46%60 177
LONZA GROUP AG-1.83%45 717
IQVIA HOLDINGS INC.28.18%44 017
CELLTRION, INC.-24.65%31 985
SEAGEN INC.-17.37%26 262
CUREVAC N.V.26.25%21 497